Pharmaceutical

Atara Biotherapeutics announced a clinical trial collaboration agreement with Merck for an upcoming Phase 1/2 trial.

Atara Biotherapeutics (NASDAQ:ATRA) announced a clinical trial collaboration agreement with Merck (NYSE:MRK) for an upcoming Phase 1/2 trial, that will see them combining their drugs to treat patients with Nasopharyngeal carcinoma.
As quoted in the press release

[The trial will] evaluate Atara Bio’s allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes (CTL), or ATA129, in combination with Merck’s anti-PD-1 (programmed death receptor-1) therapy, KEYTRUDA® (pembrolizumab), in patients with platinum resistant or recurrent EBV-associated NPC.
Atara Bio’s ATA129 is an investigational therapy in which a healthy donor’s T-cells are stimulated to recognize EBV antigens, or viral proteins, expressed in the cells of certain liquid and solid tumors. ATA129 has previously been evaluated as a single agent in Phase 1 and 2 trials that enrolled patients with a variety of EBV-positive malignancies including 14 patients with chemotherapy refractory, metastatic NPC. In these trials, evidence of radiographic response was observed and EBV-CTLs were also shown to expand after administration without concomitant lymphodepleting chemotherapy. Recent studies suggest that EBV upregulates the transcription of PD-L1 in EBV-associated solid tumors such as NPC and gastric cancer, suggesting the potential for synergy in combination with anti-PD-1 therapies, such as KEYTRUDA.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX18864.90-213.74
TSXV615.29-11.05
DOW30896.47-132.84
S&P 5003807.20-11.63
NASD11112.74-65.15
ASX6700.20-63.40

COMMODITIES

Commodities
Gold1807.07-11.76
Silver20.36-0.38
Copper3.70-0.08
Palladium1938.50-23.50
Platinum904.83-14.17
Oil106.05-3.73
Heating Oil3.83-0.12
Natural Gas5.66-0.84

DOWNLOAD FREE REPORTS

×